Published on: 15 July 2013
Skip to main content
The “Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma" is the second disease-specific treatment guideline to be published by SITC. This represents the result of a multidisciplinary collaboration between immunotherapy and genitourinary medicine experts from throughout the U.S., with input from patients and their advocates. The second guideline is a two-part publication – Volume I and Volume II – from the first Working Group (WG1) of the SITC Immune Biomarkers Task Force, which includes representatives from academia, clinical medicine, government and industry. Covering immunologic monitoring, standardization and biomarker development and validation, this report is the first to make evidence-based recommendations concerning the development, validation and regulation of biomarkers developed to predict response to cancer immunotherapy.
Metastatic Merkel cell carcinoma response to nivolumab
Frances M. Walocko, et al
Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression...
Bhaskar C. Kolla and Manish R. Patel
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
Gerald S. Falchook, et al
Application of the Immunoscore as prognostic tool for hepatocellular carcinoma
Annacarmen Petrizzo and Luigi Buonaguro
TCR diversity – a universal cancer immunotherapy biomarker?
Douglas G. McNeel
POSITION ARTICLE AND GUIDELINES
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
Brian I. Rini, et al
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
Shruti Agrawal, et al
Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas...
Debbie M. Ferns, et al
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
Ioannis F. Voutsas, et al
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I
Giuseppe V. Masucci, et al
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II
Kevin K. Dobbin, et al
View and search for all articles in the journal here.
Published on: 15 July 2013
Published on: 29 July 2013
Published on: 27 August 2013
Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
JITC welcomes submissions to the following sections:
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.
Read all of the articles here.
As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, the Society is pleased to offer its members waived article processing charges for manuscripts accepted in JITC through 2016.
Awards were presented during SITC’s 31st Annual Meeting to the first authors of two JITC articles, representing the Best Clinical/Translational and Best Basic Science Papers published in JITC. Congratulations to Zipei Feng, Sachin Puri, and Katherine Woods!
For more information please email email@example.com, call +1 414 271-2456, or visit http://sitcancer.org/journal.
The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member-driven society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The Society has become the forum for innovative discussions in the field.
Society members include nearly 1000 influential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.
It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.